Summary
The exhalation of 14CO2 derived from an i.v. tracer dose of [dimethylamine-14C]aminopyrine has been investigated in normal controls and patients. They subsequently ingested 200 mg cyclobarbital calcium in the evening and the decline in the plasma drug level over the following 2 days was measured by thin-layer chromatography. The peak specific activity of exhaled 14CO2 occurred 0.5–2 h after 14C-aminopyrine injection in the absence of liver disease and in non-cirrhotic liver disorders. It was delayed in certain patients with cirrhosis. Compared to 8 medically healthy subjects, 10 patients with acute viral hepatitis, 8 with cirrhosis and 10 with fatty liver exhibited a significantly increased half-life of 14CO2 exhalation. Normal mean values were found in 12 patients with non-cirrhotic alcoholic liver disease and in 14 patients with non-hepatic diseases. The cyclobarbital (CB) half-life was prolonged and the clearance reduced in patients with viral hepatitis, cirrhosis, or alcoholic liver damage as compared to data from 17 control subjects. Due to a larger apparent volume of distribution, patients with fatty liver disease had an increased CB half-life, although its clearance was normal. A close negative correlation was detected between the clearance and the logarithm of the CB level measured 36 h after drug ingestion. The oral CB test evaluated from a single blood sample taken about 36 h after drug administration appears to be a useful indicator of human drug metabolising capacity. Discrimination between patients with and without disordered liver function was similar in the two drug elimination tests.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Branch RA (1982) Drugs as indicators of hepatic function. Hepatology 2: 97–105
Hepner GW, Vesell ES (1975) Quantitative assessment of hepatic function by breath analysis after oral administration of [14C]-aminopyrine. Ann Int Med 83: 632–638
Saunders JB, Lewis KO, Paton A (1980) Early diagnosis of alcoholic cirrhosis by the aminopyrine breath test. Gastroenterology 79: 112–114
Hepner GW, Vesell ES (1974) Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med 291: 1384–1388
Bircher J, Kuepfer A, Gikalov I, Preisig R (1976) Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 20: 484–492
Noordhoek J, Dees J, Savanije-Chapel EM, Wilson JHP (1978) Output of 14CO2 in breath after oral administration of (14C-methyl)aminopyrine in hepatitis, cirrhosis and hepatic bilharziasis: its relationship to aminopyrine pharmacokinetics. Eur J Clin Pharmacol 13: 223–229
Henry DA, Sharpe G, Chaplain S, Cartwright S, Kitchingman G, Bell GD, Langman MJS (1979) The [14C]-aminopyrine breath-test. A comparison of different forms of analysis. Br J Clin Pharmacol 8: 539–545
Pauwels S, Geubel AP, Dive C, Beckers C (1982) Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases. Dig Dis Sci 27: 49–56
Breyer-Pfaff U, Harder M, Egberts EH (1982) Plasma levels of parent drug and metabolites in the intravenous aminopyrine breath test. Eur J Clin Pharmacol 21: 521–528
Alvin J, McHorse T, Hoyumpa A, Bush MT, Schenker S (1975) The effect of liver disease in man on the disposition of phenobarbital. J Pharmacol Exp Ther 192: 224–235
Inaba T, Tang BK, Endrenyi L, Kalow W (1976) Amobarbital — probe of hepatic drug oxidation in man. Clin Pharmacol Ther 20: 439–444
Zilly W, Breimer DD, Richter E (1978) Hexobarbital disposition in compensated cirrhosis of liver. Clin Pharmacol Ther 23: 525–534
Hoyumpa Jr AM, Schenker S (1982) Major drug interactions: effect of liver disease, alcohol, and malnutrition. Ann Rev Med 33: 113–149
Breyer-Pfaff U, Jerg H, Petruch F (1979) Cyclobarbital as a test substance for oxidative drug metabolism in man. Findings in neuropsychiatric patients. Eur J Clin Pharmacol 15: 433–441
Breyer-Pfaff U, Weber M, Seyfert H, Egberts EH (1983) Cyclobarbital and aminopyrine elimination as indices of hepatic drug metabolism in medical patients. Naunyn-Schmiedeberg's Arch Pharmacol 322 [Suppl]: R 127
Breyer U, Villumsen D (1975) Thin-layer chromatographic determination of barbiturates and phenytoin in serum and blood. J Chromatogr 115: 493–500
Sachs L (1968) Statistische Auswertungsmethoden. Springer, Berlin Heidelberg New York
Irving CS, Schoeller DA, Nakamura KI, Baker AL, Klein PD (1982) The aminopyrine breath-test as a measure of liver function. A quantitative description of its metabolic basis in normal subjects. J Lab Clin Med 100: 356–373
Cummings AJ, Martin BK, Park GS (1967) Kinetic considerations relating to the accrual and elimination of drug metabolites. Br J Pharmacol Chemother 29: 136–149
Winchell HS, Stahelin H, Kusubov N, Slanger B, Fish M, Pollycove M, Lawrence JH (1970) Kinetics of CO2-HCO −3 in normal adult males. J Nucl Med 11: 711–715
Schoeller DA, Baker AL, Monroe PS, Krager PS, Schneider JF (1982) Comparison of different methods of expressing results of the aminopyrine breath test. Hepatology 2: 455–462
Mawer GE, Miller NE, Turnberg LA (1972) Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol 44: 549–560
Ossenberg FW, Denis P, Pointard L, Benhamou JP (1973) Pentobarbital pharmacokinetics in cirrhosis. Digestion 8: 448–449
Carulli N, Manenti F, Ponz de Leon M, Ferrari A, Salvioli G, Gallo M (1975) Alteration of drug metabolism during cholestasis in man. Eur J Clin Invest 5: 455–462
Breimer DD, Zilly W, Richter E (1975) Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. Clin Pharmacol Ther 18: 433–440
Fretwurst F, Halberkann J, Reiche F (1932) Phanodorm und seine Wiederausscheidung mit dem Harn. Muench Med Wochenschr 79: 1429–1432
Abernethy DR, Greenblatt DJ (1982) Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 7: 108–124
Weber M (1982) Kinetic und Bindung von Cylcobarbital bei internistischen Patienten. Thesis Universität Tübingen, FRG
Døssing M, Poulsen HE, Andreasen PB, Tygstrup N (1982) A simple method for determination of antipyrine clearance. Clin Pharmacol Ther 32: 392–396
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Breyer-Pfaff, U., Seyfert, H., Weber, M. et al. Assessment of drug metabolism in hepatic disease: Comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test. Eur J Clin Pharmacol 26, 95–101 (1984). https://doi.org/10.1007/BF00546715
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00546715